Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.2%

16 terminated/withdrawn out of 93 trials

Success Rate

80.2%

-6.3% vs industry average

Late-Stage Pipeline

15%

14 trials in Phase 3/4

Results Transparency

65%

42 of 65 completed trials have results

Key Signals

8 recruiting42 with results14 terminated

Enrollment Performance

Analytics

Phase 2

37(44.0%)

Phase 1

33(39.3%)

Phase 3

13(15.5%)

Phase 4

1(1.2%)

84Total

Phase 2(37)

Phase 1(33)

Phase 3(13)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (93)

Showing 20 of 93 trials

NCT06088290Phase 3Recruiting

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Role: lead

NCT04305548Phase 2Recruiting

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Role: collaborator

NCT04383119Phase 2Recruiting

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Role: collaborator

NCT05153239Phase 3Active Not Recruiting

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Role: lead

NCT02805725Phase 1Completed

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Role: collaborator

NCT06050434Terminated

Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Role: collaborator

NCT05841563Phase 1Recruiting

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Role: lead

NCT05072106Phase 1Completed

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Role: lead

NCT03085225Phase 1Completed

Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Role: collaborator

NCT05063318Phase 1Completed

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Role: lead

NCT05835609Phase 1Recruiting

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

Role: lead

NCT02611024Phase 1Completed

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Role: lead

NCT04358237Phase 1Completed

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

Role: collaborator

NCT06524583Phase 2Recruiting

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Role: collaborator

NCT03164980Phase 4Terminated

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Role: collaborator

NCT06766825Phase 2Recruiting

Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)

Role: collaborator

NCT04784559Phase 3Terminated

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Role: lead

NCT05121740Phase 1Completed

Extension Study in a Cohort of Adult Patients With COVID-19 Infection

Role: lead

NCT05076396Phase 1Recruiting

PM14 Administered Intravenously to Patients with Advanced Solid Tumors

Role: lead

NCT03838744Phase 2Completed

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Role: collaborator